Richard was previously Sensyne’s Chief Investment Officer. Michael Norris, Sensyne’s former Interim Chief Financial Officer, and Geoff Race will join the Sensyne Board as Non-Executive Directors.
Sir Bruce Keogh, Chairman of Sensyne Health, said: “I am delighted to welcome Richard, Geoff and Michael to the Board of Sensyne. I would like to thank Michael for his excellent service as Interim CFO and I am delighted he has agreed to stay with the business as a Non-Executive Director. These senior appointments will help us boost commercial momentum and accelerate the scaling of the business internationally.”
Dr Pye has more than 15 years’ experience in corporate finance and investor relations in the public market life science sector. Prior to joining Sensyne, Richard was at Summit Therapeutics plc, an AIM and Nasdaq-listed biopharmaceutical company, where he held a number of leadership roles including most recently the position of Vice President of Corporate Affairs and Investor Relations.
Michael Norris has served as Sensyne’s Interim CFO since March 2020 and has more than 20 years of experience working with public and private companies in the technology and life sciences sectors. Michael is currently also Director and CFO of Beckley Psytech Ltd, a company developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines.
Geoff Race is the co-founder, EVP, CFO, and CBO of Nasdaq listed biopharmaceutical company Minerva Neurosciences Inc.
Sensyne has also announced that its SYNE-COVTM machine learning algorithm for COVID risk prediction has achieved regulatory approval for use in the UK.